While the role of <i>KRAS</i> gene mutations has been widely accepted for predicting responses to anti-EGFR therapy in patients with colorectal cancer, although this study was based on observation of a single case it gives hope that some <i>KRAS</i> gene mutation may have favorable prognosis. This evidence concerns the gene EGFR and colorectal cancer.